Targeson develops, manufactures and markets ultrasound imaging agents for perfusion and molecular imaging applications in the research market.

Targeson’s molecular targeted agents are gas-encapsulated microspheres that, when coated with specific targeting ligand molecules, can adhere to molecular markers of disease. This technique can be used in animal models of a wide variety of diseases, such as cancer, heart attack, atherosclerosis and cardiovascular plaque, organ transplant rejection, and inflammatory bowel disease.

Targeson’s commercial products include:

Targestar® P,Perfusion contrast agent to enhance and quantify blood flow and vascular function.

Targestar P-HF,Perfusion contrast agent for use with high frequency scanners for blood flow and vascular function.

Targestar SA,Targetable contrast agent enabling a biotinylated antibody/biomolecule to be coupled to a microsphere.

Visistar® Integrin,Targeted contrast agent that binds integrin for imaging angiogenesis and tumor growth.

Visistar VEGFR2,Targeted contrast agent with a VEGFR2 binding ligand for imaging angiogenesis and tumor growth.

Visistar VCAM-1,Targeted contrast agent targeted to VCAM-1 for molecular imaging of inflammation.

Targesphere™,Cationic delivery agent used for in vivo and in vitro transfection.